CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞治疗继发性中枢神经系统受累套细胞淋巴瘤的临床疗效与安全性
英文原题：Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
查看英文原题
Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
关于嵌合抗原受体（CAR）T 细胞治疗继发中枢神经系统（SCNS）受累套细胞淋巴瘤（MCL）的结局数据有限。我们收集了 3 家美国学术医疗中心接受抗 CD19 CAR-T 细胞治疗的 10 例 MCL 合并 SCNS 受累患者。中枢神经系统和全身的客观缓解率分别为 86% 和 90%，1 年无进展生存率为 47%。7 例患者发生免疫效应细胞相关神经毒性综合征（2 例 1 级，5 例 3 级）。结果提示，在这一患者群体中，抗 CD19 CAR-T 细胞治疗具有可行性；仍可能需要更多关于神经毒性的相关数据。
展开英文摘要原文
Data describing outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with secondary central nervous system (SCNS) involvement of mantle cell lymphoma (MCL) are limited.
We identified 10 patients with MCL and SCNS involvement treated with anti-CD19 CAR T-cell therapy at three US academic centres. Frequent objective responses were observed in the CNS (86%) and systemically (90%), and the 1-year progression-free survival was 47%. Seven patients developed immune-effector-cell-associated-neurotoxicity-syndrome (n = 2 Grade 1, n = 5 Grade 3).
Our results suggest that anti-CD19 CAR T-cell therapy in this setting is feasible and additional data regarding neurotoxicity in this population may be warranted.
论文信息
- 作者
- Ryan CE、Zon RL、Redd R、Fisher DC、Shouval R、Kumar A、Crombie JL、Sadrzadeh H
- 单位
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.United States
- 文献类型
- 美国 NIH 资助研究
- 期刊
- British journal of haematology2023 Dec
- 原文标识
- PubMed 37584155 · DOI 10.1111/bjh.19037
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →